Clinical trials: Transplant Patients
Non-Melanoma Skin Carcinoma
Evaluation Of The Importance Of Risk-Factor Adjustment For Assessing The Relationship Between Voriconazole Utilization And The Development Of Non-Melanoma Skin Cancer Among Lung And Heart/Lung Transplant Patients, 2002-2009g
The primary objective of the study is to assess the relationship (both crude and adjusted) between voriconazole utilization and the development of non-melanoma skin cancer among adult patients who received a lung or heart/lung…
- Trial name
- NCT01480219
- Testing
- voriconazole (Vfend), no voriconazole (Vfend)
- Volunteers
- 467 people
- Sponsor
- Pfizer
Adenovirus Infection, BK Virus Infection
Posoleucel (ALVR105, Formerly Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant
This is a Phase 2 study to evaluate posoleucel (ALVR105, formerly Viralym-M); an allogeneic, off-the-shelf multi-virus specific T cell therapy that targets six viral pathogens: BK virus, cytomegalovirus, adenovirus, Epstein-Barr…
- Conditions
- Adenovirus Infection, BK Virus Infection, Cytomegalovirus Infections, Epstein-Barr Virus Infections
- Trial name
- Prevent (NCT04693637)
- Testing
- Posoleucel (ALVR105)
- Where
- 16 sites in United States
- Volunteers
- 26 people
- Sponsor
- AlloVir
Tibia Fracture
OIF/β-TCP in Patients With Open Tibial Fractures in Need of Bone Grafting
A prospective, randomized, evaluator-blinded, controlled study for subjects with open tibial fractures classified as Gustilo type II, IIIA or IIIB (see Appendix 1) who will receive bone graft implantation for the potential of…
- Trial name
- NCT04960722
- Testing
- OIF/β-TCP
- Where
- Taiwan
- Volunteers
- 35 people
- Sponsor
- BioGend Therapeutics Co.Ltd
Liver Transplant
Efficacy and Safety of Basiliximab in Hepatitis C Virus Positive Patients Undergoing Liver Transplantation
The natural history of HCV infection in liver transplant recipients may be accelerated when compared to that in patients with normal immune systems.
- Trial name
- NCT00238901
- Testing
- Basiliximab
- Volunteers
- 194 people
- Sponsor
- Novartis
Delayed Graft Function
Study on Delayed Graft Function Using Paired Kidneys
The study is designed to evaluate the safety and efficacy of an intravenously administered drug in recipients of kidneys from cardiac death donors who are risk for developing delayed graft function.
- Trial name
- NCT01561599
- Testing
- BB3, Normal Saline
- Where
- 3 sites in Netherlands, Spain and 1 more
- Volunteers
- 12 people
- Sponsor
- Angion Biomedica Corp
Multiple Myeloma
Study to Determine Efficacy and Safety of Lenalidomide Plus Low-dose Dexamethasone Versus Melphalan, Prednisone, Thalidomide in Patients With Previously Untreated Multiple Myeloma
The purpose of this study is to compare the safety and efficacy of Lenalidomide plus low dose dexamethasone to that of the combination of melphalan, prednisone and thalidomide.
- Trial name
- FIRST (NCT00689936)
- Testing
- Lenalidomide and low-dose dexamethasone, Lenalidomide plus low-dose dexamethasone given for 18 four-week cycles, Melphalan, Prednisone and Thalidomide
- Where
- 288 sites in United States, Australia and 17 more
- Volunteers
- 1,623 people
- Sponsor
- Celgene
Kidney Transplant
Tacrolimus and Risk Factors for Glucose Metabolism Disorders in Kidney Transplant Patients
Many people who receive a kidney transplant develop problems with how their body processes sugar (glucose). This includes conditions like prediabetes and diabetes, which can lead to more health issues, such as heart problems and…
- Trial name
- TARGET (NCT06833463)
- Testing
- LCP Tacro (tacrolimus)
- Where
- 6 sites in Poland
- Volunteers
- 120 people
- Sponsor
- Chiesi Poland Sp. z o.o.
Hepatocellular Carcinoma (HCC)
A Study Evaluating the Safety and Efficacy of Selective Internal Radiation Therapy (SIRT) Using SIR-Spheres® Y-90 Resin Microspheres to Bridge or Downstage Patients With Hepatocellular Carcinoma (HCC) to Liver Transplant or Resection and Elicit Pathologic Necrosis.
This clinical investigation involves the use of an approved medical device (SIR-Spheres®) for a new purpose in patients with certain types of liver cancer.
- Trial name
- NCT07663487
- Testing
- SIR-Spheres Selectively Delivered to Liver Tumor
- Volunteers
- 78 people
- Sponsor
- Sirtex Medical
cGvHD
A Phase II Study Evaluating the Efficacy and Safety of ABSK021 (Pimicotinib)) in the Treatment of cGvHD Chronic Graft Versus Host Disease (cGvHD)
This is a multicenter, single arm, open label phase II clinical study in China. This study will evaluate the efficacy and safety of ABSK021 (Pimicotinib) in the treatment of patients with cGvHD who failed first-line therapy.
- Trial name
- NCT06186804
- Testing
- ABSK021
- Where
- 14 sites in China
- Volunteers
- 64 people
- Sponsor
- Abbisko Therapeutics Co, Ltd
Acute Renal Transplant Rejection
NI-0401 in Patients With Acute Renal Allograft Rejection
The purpose of the study is to determine the safety and tolerability of NI-0401 and whether NI-0401 can reverse BpACR.
- Trial name
- NCT00805909
- Testing
- NI-0401
- Where
- France
- Volunteers
- 12 people
- Sponsor
- Light Chain Bioscience - Novimmune SA
Psoriasis, Skin Diseases
A Phase 2b Study of Baricitinib in Participants With Moderate to Severe Psoriasis
This is a dose-ranging study designed to investigate the efficacy and safety of Baricitinib in the treatment of participants with moderate to severe, chronic plaque psoriasis as assessed by the Psoriasis Area and Severity Index…
- Conditions
- Psoriasis, Skin Diseases, Skin Diseases, Papulosquamous
- Trial name
- NCT01490632
- Testing
- Baricitinib
- Where
- 35 sites in United States, Canada and 2 more
- Volunteers
- 271 people
- Sponsor
- Eli Lilly and Company
Acute Myeloid Leukemia, Relapsed, Adult
A Study of the Tumor-targeting Human F16IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Very Low-dose Cytarabine in Patients With AML Relapse After Allogeneic Hematopoietic Stem Cell Transplantation
Phase I, open label, non-randomized, multicenter, prospective dose escalation study of F16IL2 in combination with very low-dose cytarabine in subjects with acute myeloid leukemia relapse after allogeneic hematopoietic stem cell…
- Trial name
- NCT02957032
- Testing
- F16IL2, cytarabine
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- Philogen S.p.A.
Burn Scar, Burn Wound
Post-Operative Use of FS2 to Mitigate Scarring in Burn Patients
The goal of this study is to see how an ingredient called kynurenic acid (which we named "FS2") affects scar formation in people with burn injuries that need skin graft surgery.
- Trial name
- NCT06807021
- Testing
- IP1 control cream (Vehicle base), IP2 - 0.5% w/w FS2
- Where
- 2 sites in Canada
- Volunteers
- 70 people
- Sponsor
- Birch BioMed Inc
Liver Transplant, Kidney Transplant
A 5 Year Follow-up of Patients Who Were Previously Enrolled Into an Advagraf Trial Following a Liver or Kidney Transplant
The purpose of this study is to evaluate the impact of Advagraf, prolonged-release, once daily tacrolimus formulation, on long-term graft survival in kidney and liver allograft recipients.
- Trial name
- ADDRESS (NCT02057484)
- Testing
- Tacrolimus
- Where
- 145 sites in Austria, Belarus and 22 more
- Volunteers
- 2,300 people
- Sponsor
- Astellas Pharma Europe Ltd.
Graft Failure
Study to Investigate the Pharmacokinetics, Pharmacodynamics and Assess the Efficacy and Safety to Support Dose Selection of Emapalumab in Pre-empting Graft Failure in Patients at High Risk After HSCT.
This study is designed as an open-label, single arm, proof of concept study in order to determine the appropriate emapalumab dosing regimen neutralizing IFNγ in patients at risk of GF.
- Trial name
- NCT04731298
- Testing
- Emapalumab
- Where
- 5 sites in Australia, Canada and 1 more
- Volunteers
- 2 people
- Sponsor
- Swedish Orphan Biovitrum
ESRD (End-Stage Renal Disease), Kidney Transplantation
Study to Evaluate the Safety and Efficacy of the GGTA1 KO Thymokidney in Patients With ESRD
The purpose of this study is to evaluate the safety and efficacy of the GGTA1 KO Thymokidney in patients with end-stage renal disease (ESRD) who are either not eligible for conventional allogeneic kidney transplantation (Group 1)…
- Conditions
- ESRD (End-Stage Renal Disease), Kidney Transplantation, Xenotransplantation
- Trial name
- EXTEND (NCT07224763)
- Testing
- GGTA1 KO Thymokidney
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- United Therapeutics
Limbal Stem Cell Deficiency Due to Ocular Burn
Follow-up Study After ACLSCT for Restoration of Corneal Epithelium in Patients With LSCD Due to Ocular Burns
This is a multinational, multicentre, prospective, non-pharmacological follow-up study of the clinical trial HOLOCORE. All patients transplanted with Holoclar in the HOLOCORE clinical trial who consent to participate will be…
- Trial name
- HOLOCORE-FU (NCT03288844)
- Testing
- Ophthalmologic examinations, Digital pictures, QoL Questionnaires
- Where
- Italy
- Volunteers
- 47 people
- Sponsor
- Holostem s.r.l.
Abdominal Aortic Aneurysm
Global Post-market Registry for the Treovance Stent-graft.
Patients with abdominal aortic aneurysms (AAA) suitable for endovascular aortic repair (EVAR) with Treovance were eligible to participate.
- Trial name
- RATIONALE (NCT03449875)
- Testing
- TREOVANCE® Stent-Graft with Navitel® Delivery System
- Where
- 32 sites in Chile, Denmark and 15 more
- Volunteers
- 202 people
- Sponsor
- Bolton Medical
Acute Lymphoblastic Leukemia (ALL), Acute Myelogenous Leukemia (AML)
Pilot Study Evaluating Safety & Efficacy of DCBT: NiCord® & UNM CBU to Patients With Hematological Malignancies
Pilot Study Evaluating the Safety and Efficacy of a Co-Transplantation of NiCord®, a UCB-derived ex Vivo Expanded Population of Stem and Progenitor Cells with a Second, Unmanipulated CBU in Patients with Hematological Malignancies
- Conditions
- Acute Lymphoblastic Leukemia (ALL), Acute Myelogenous Leukemia (AML), Myelodysplastic Syndrome (MDS), Non-Hodgkin's Lymphoma
- Trial name
- NCT01221857
- Testing
- NiCord®
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Gamida Cell ltd
Hepatitis B, Chronic
Nabi-HB Administered Subcutaneously in Patients With Hepatitis B Virus Post Liver Transplantation
A phase 3, multicenter, open label study to assess the safety and efficacy of Nabi-HB, administered subcutaneously in patients with Hepatitis B Virus Associated Liver Disease who underwent liver transplantation.
- Trial name
- Nabi-HB-SC (NCT00800787)
- Testing
- Nabi-HB
- Sponsor
- Biotest Pharmaceuticals Corporation